Department of Pediatrics,
Center for Genomic Engineering,
Masonic Cancer Center
Beau R. Webber has not added Biography.
If you are Beau R. Webber and would like to personalize this page please email our Author Liaison for assistance.
TALEN-based gene correction for epidermolysis bullosa.
Molecular therapy : the journal of the American Society of Gene Therapy Jun, 2013 | Pubmed ID: 23546300
DNA methylation of Runx1 regulatory regions correlates with transition from primitive to definitive hematopoietic potential in vitro and in vivo.
Blood Oct, 2013 | Pubmed ID: 24030384
Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis.
The American journal of pathology Jul, 2014 | Pubmed ID: 24832557
Fanconi anemia gene editing by the CRISPR/Cas9 system.
Human gene therapy Feb, 2015 | Pubmed ID: 25545896
From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.
Molecular therapy : the journal of the American Society of Gene Therapy Jun, 2015 | Pubmed ID: 25803200
In Vitro T-Cell Generation From Adult, Embryonic, and Induced Pluripotent Stem Cells: Many Roads to One Destination.
Stem cells (Dayton, Ohio) Nov, 2015 | Pubmed ID: 26227158
Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases.
Molecular therapy : the journal of the American Society of Gene Therapy Mar, 2016 | Pubmed ID: 26502778
CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia.
Stem cells and development 10, 2016 | Pubmed ID: 27538887
Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology.
Journal of inherited metabolic disease 03, 2017 | Pubmed ID: 27743312
CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa.
NPJ Regenerative medicine , 2016 | Pubmed ID: 28250968
Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells.
Blood 06, 2017 | Pubmed ID: 28533309
CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells.
International journal of molecular sciences Jun, 2017 | Pubmed ID: 28613254
Dermatopontin in Bone Marrow Extracellular Matrix Regulates Adherence but Is Dispensable for Murine Hematopoietic Cell Maintenance.
Stem cell reports 09, 2017 | Pubmed ID: 28844660
Rapid generation of Col7a1 mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells.
Laboratory investigation; a journal of technical methods and pathology 10, 2017 | Pubmed ID: 28892093
Rapid DNA replication origin licensing protects stem cell pluripotency.
eLife 11, 2017 | Pubmed ID: 29148972
CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression.
International journal of molecular sciences Mar, 2018 | Pubmed ID: 29565806
Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease.
Scientific reports 08, 2018 | Pubmed ID: 30108345
Highly multiplexed genome engineering using CRISPR/Cas9 gRNA arrays.
PloS one , 2018 | Pubmed ID: 30222773
EditR: A Method to Quantify Base Editing from Sanger Sequencing.
The CRISPR journal 06, 2018 | Pubmed ID: 31021262
Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs.
The Journal of investigative dermatology 02, 2020 | Pubmed ID: 31437443
A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy.
Molecular therapy : the journal of the American Society of Gene Therapy 01, 2020 | Pubmed ID: 31704085
Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors.
Nature communications 11, 2019 | Pubmed ID: 31745080
Author Correction: Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors.
Nature communications Dec, 2019 | Pubmed ID: 31811147
Efficient targeted integration directed by short homology in zebrafish and mammalian cells.
eLife May, 2020 | Pubmed ID: 32412410
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유